CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer.

about

CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer.

Item

http://www.wikidata.org/entity/Q52592862

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

CDK4/6 inhibition as maintenan ...... h grade serous ovarian cancer.

@en

CDK4/6 inhibition as maintenan ...... h grade serous ovarian cancer.

@nl

type

Item

label

CDK4/6 inhibition as maintenan ...... h grade serous ovarian cancer.

@en

CDK4/6 inhibition as maintenan ...... h grade serous ovarian cancer.

@nl

prefLabel

CDK4/6 inhibition as maintenan ...... h grade serous ovarian cancer.

@en

CDK4/6 inhibition as maintenan ...... h grade serous ovarian cancer.

@nl

P1476

CDK4/6 inhibition as maintenan ...... h grade serous ovarian cancer.

@en

P2093

Alex Cole

http://www.w3.org/2001/XMLSchema#string

Kun Yang

http://www.w3.org/2001/XMLSchema#string

Mangala Iyengar

http://www.w3.org/2001/XMLSchema#string

Patrick O'Hayer

http://www.w3.org/2001/XMLSchema#string

Ronald J Buckanovich

http://www.w3.org/2001/XMLSchema#string

Tara Sebastian

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Cancer statistics, 2015

Targeting CDK4 and CDK6: From Discovery to Therapy

Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer

The senescence-associated secretory phenotype: the dark side of tumor suppression

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.

P304

15658-15672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24585

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lan Coffman

P577

2018-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29644000

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5884655

http://www.w3.org/2001/XMLSchema#string